Category: All HBOC

LitAlert ~~ GeneLit.com

    • Breast imaging, breast surgery, and cancer genetics in the age of COVID-19.
    • Yin K, Preeti Singh P, Drohan B, Hughes KS.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33113. Epub ahead of print

    • Patterns of cancer family history and genetic counseling eligibility among African Americans with breast, prostate, lung, and colorectal cancers: A Detroit Research on Cancer Survivors cohort study.
    • Purrington KS, Schwartz AG, Ruterbusch JJ, Manning MA, Nair M, Wenzlaff AS.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33126. Epub ahead of print

    • BRCA1 mutations in cancer: coordinating deficiencies in homologous recombination with tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Aug 3:canres.1830.2020. doi: 10.1158/0008-5472.CAN-20-1830. Epub ahead of print.
    • Review

    • Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer.
    • Velázquez C, De Leeneer K, Esteban-Cardeñosa EM, Avila Cobos F, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Claes KB, Durán M, Infante M.
    • Cancers (Basel). 2020 Aug 3;12(8):E2151. doi: 10.3390/cancers12082151.

    • Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore.
    • Shaw T, Chan SH, Teo JX, Chong ST, Li ST, Courtney E, Ishak D, Sankar H, Ang ZLT, Chiang J, Loh M, Zhou L, Lee SC, Yeh HY, Kolinjivadi AM, Lim WK, Ngeow J.
    • Int J Cancer. 2020 Aug 3. doi: 10.1002/ijc.33241. Epub ahead of print.

    • BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
    • Merlino L, Chiné A, Galli C, Piccioni MG.
    • Minerva Ginecol. 2020 Aug 3. doi: 10.23736/S0026-4784.20.04624-9. Epub ahead of print.
    • Review

    • Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
    • Wood ME, McKinnon W, Garber J.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13969. Epub ahead of print.
    • Review

    • Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates.
    • Altinoz A, Al Ameri M, Qureshi W, Boush N, Nair SC, Abdel-Aziz A.
    • Breast. 2020 Jul 27;53:119-124. doi: 10.1016/j.breast.2020.07.005. Epub ahead of print.

    • PARP inhibitors in castration-resistant prostate cancer.
    • Tripathi A, Balakrishna P, Agarwal N.
    • Cancer Treat Res Commun. 2020 Jul 22;24:100199. doi: 10.1016/j.ctarc.2020.100199. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • BRCA1 mutations in cancer: coordinating deficiencies in homologous recombination with tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Aug 3:canres.1830.2020. doi: 10.1158/0008-5472.CAN-20-1830. Epub ahead of print.
    • Review

    • Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer.
    • Velázquez C, De Leeneer K, Esteban-Cardeñosa EM, Avila Cobos F, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Claes KB, Durán M, Infante M.
    • Cancers (Basel). 2020 Aug 3;12(8):E2151. doi: 10.3390/cancers12082151.

    • Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore.
    • Shaw T, Chan SH, Teo JX, Chong ST, Li ST, Courtney E, Ishak D, Sankar H, Ang ZLT, Chiang J, Loh M, Zhou L, Lee SC, Yeh HY, Kolinjivadi AM, Lim WK, Ngeow J.
    • Int J Cancer. 2020 Aug 3. doi: 10.1002/ijc.33241. Epub ahead of print.

    • BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
    • Merlino L, Chiné A, Galli C, Piccioni MG.
    • Minerva Ginecol. 2020 Aug 3. doi: 10.23736/S0026-4784.20.04624-9. Epub ahead of print.
    • Review

    • Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
    • Wood ME, McKinnon W, Garber J.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13969. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease.
    • Cen C, Chun J, Schnabel F.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13964. Online ahead of print.
    • Review

    • European polygenic risk score for prediction of breast cancer shows similar performance in Asian women.
    • Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, Ho PJ, Dennis J, Tyrer JP, Bolla MK, Michailidou K, Wang Q, Kang D, Choi JY, Jamaris S, Shu XO, Yoon SY, Park SK, Kim SW, Shen CY, Yu JC, Tan EY, Chan PMY, Muir K, Lophatananon A, Wu AH, Stram DO, Matsuo K, Ito H, Chan CW, Ngeow J, Yong WS, Lim SH, Lim GH, Kwong A, Chan TL, Tan SM, Seah J, John EM, Kurian AW, Koh WP, Khor CC, Iwasaki M, Yamaji T, Tan KMV, Tan KTB, Spinelli JJ, Aronson KJ, Hasan SN, Rahmat K, Vijayananthan A, Sim X, Pharoah PDP, Zheng W, Dunning AM, Simard J, van Dam RM, Yip CH, Taib NAM, Hartman M, Easton DF, Teo SH, Antoniou AC.
    • Nat Commun. 2020 Jul 31;11(1):3833. doi: 10.1038/s41467-020-17680-w.

    • European polygenic risk score for prediction of breast cancer shows similar performance in Asian women.
    • Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, Ho PJ, Dennis J, Tyrer JP, Bolla MK, Michailidou K, Wang Q, Kang D, Choi JY, Jamaris S, Shu XO, Yoon SY, Park SK, Kim SW, Shen CY, Yu JC, Tan EY, Chan PMY, Muir K, Lophatananon A, Wu AH, Stram DO, Matsuo K, Ito H, Chan CW, Ngeow J, Yong WS, Lim SH, Lim GH, Kwong A, Chan TL, Tan SM, Seah J, John EM, Kurian AW, Koh WP, Khor CC, Iwasaki M, Yamaji T, Tan KMV, Tan KTB, Spinelli JJ, Aronson KJ, Hasan SN, Rahmat K, Vijayananthan A, Sim X, Pharoah PDP, Zheng W, Dunning AM, Simard J, van Dam RM, Yip CH, Taib NAM, Hartman M, Easton DF, Teo SH, Antoniou AC.
    • Nat Commun. 2020 Jul 31;11(1):3833. doi: 10.1038/s41467-020-17680-w.

    • LitAlert ~~ GeneLit.com

    • Communication skills training for healthcare professionals in providing genetic counseling: A scoping literature review.
    • Medendorp NM, van den Heuvel LM, Han PKJ, Hillen MA, Smets EMA.
    • Patient Educ Couns. 2020 Aug 1:S0738-3991(20)303918. doi: 10.1016/j.pec.2020.07.018. Epub ahead of print.
    • Review

    • Evidence for Increased Susceptibility for Breast Cancer from Exposure to Ionizing Radiation Due to Familial Breast Cancer History: Results from the Swedish Hemangioma Cohort.
    • Eidemüller M, Holmberg E, Lundell M, Karlsson P.
    • Am J Epidemiol. 2020 Jul 31:kwaa163. doi: 10.1093/aje/kwaa163. Epub ahead of print.

    • A Modern Dilemma: How Experts Grapple with Ambiguous Genetic Test Results.
    • Scherr CL, Ross Arguedas AA, Getachew-Smith H, Marshall-Fricker C, Shrestha N, Brooks K, Fischhoff B, Vadaparampil ST.
    • Med Decis Making. 2020 Jul;40(5):655-668. doi: 10.1177/0272989X20935864.

    • LitAlert ~~ GeneLit.com

    • PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.
    • Zhang M, Zhang J.
    • Biosci Rep. 2020 Jul 30:BSR20201648. doi: 10.1042/BSR20201648. Epub ahead of print.

    • Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    • Geuzinge HA, Obdeijn IM, Rutgers EJT, Saadatmand S, Mann RM, Oosterwijk JC, Tollenaar RAEM, de Roy van Zuidewijn DBW, Lobbes MBI, van ‘t Riet M, Hooning MJ, Ausems MGEM, Loo CE, Wesseling J, Luiten EJT, Zonderland HM, Verhoef C, Heijnsdijk EAM, Tilanus-Linthorst MMA, de Koning HJ, for the Familial MRI Screening (FaMRIsc) Study group.
    • JAMA Oncol. 2020 Jul 30. doi: 10.1001/jamaoncol.2020.2922. Epub ahead of print.

    • Breast MRI texture analysis for prediction of BRCA-associated genetic risk.
    • Vasileiou G, Costa MJ, Long C, Wetzler IR, Hoyer J, Kraus C, Popp B, Emons J, Wunderle M, Wenkel E, Uder M, Beckmann MW, Jud SM, Fasching PA, Cavallaro A, Reis A, Hammon M.
    • BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.

    • Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
    • Alenezi WM, Fierheller CT, Recio N, Tonin PN.
    • Genes (Basel). 2020 Jul 27;11(8):E856. doi: 10.3390/genes11080856.

    • Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts.
    • Di Raimo T, Angelini F.
    • J Clin Med. 2020 Jul 25;9(8):E2377. doi: 10.3390/jcm9082377.

    • Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
    • Go A, Jang JW, Lee W, Ha JD, Kim HJ, Nam HJ.
    • Eur J Med Chem. 2020 Jul 19;204:112635. doi: 10.1016/j.ejmech.2020.112635. Epub ahead of print.

    • Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study.
    • Jang JH, Arora N, Kwon JS, Hanley GE.
    • J Obstet Gynaecol Can. 2020 Apr 27:S1701-2163(20)30336-4. doi: 10.1016/j.jogc.2020.03.022. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Breast MRI texture analysis for prediction of BRCA-associated genetic risk.
    • Vasileiou G, Costa MJ, Long C, Wetzler IR, Hoyer J, Kraus C, Popp B, Emons J, Wunderle M, Wenkel E, Uder M, Beckmann MW, Jud SM, Fasching PA, Cavallaro A, Reis A, Hammon M.
    • BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.

    • Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
    • Alenezi WM, Fierheller CT, Recio N, Tonin PN.
    • Genes (Basel). 2020 Jul 27;11(8):E856. doi: 10.3390/genes11080856.

    • Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts.
    • Di Raimo T, Angelini F.
    • J Clin Med. 2020 Jul 25;9(8):E2377. doi: 10.3390/jcm9082377.

    • Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
    • Go A, Jang JW, Lee W, Ha JD, Kim HJ, Nam HJ.
    • Eur J Med Chem. 2020 Jul 19;204:112635. doi: 10.1016/j.ejmech.2020.112635. Epub ahead of print.

    • Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study.
    • Jang JH, Arora N, Kwon JS, Hanley GE.
    • J Obstet Gynaecol Can. 2020 Apr 27:S1701-2163(20)30336-4. doi: 10.1016/j.jogc.2020.03.022. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    • Zhang J, Yao L, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Jul 28. doi: 10.1002/ijc.33234. Epub ahead of print.

    • Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
    • Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I.
    • Ann Surg Oncol. 2020 Jul 27. doi: 10.1245/s10434-020-08889-6. Epub ahead of print.

    • Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • Arch Gynecol Obstet. 2020 Jul 27. doi: 10.1007/s00404-020-05690-4. Epub ahead of print.

    • Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    • Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    • Cancer Res Treat. 2020 Jul 27. doi: 10.4143/crt.2020.557. Epub ahead of print.

    • Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
    • Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, Chatterjee-Paer S, Carlson AD, Holcomb KM.
    • J Gen Intern Med. 2020 Jul 27. doi: 10.1007/s11606-020-06064-x. Epub ahead of print.

    • Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
    • Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J.
    • Nat Commun. 2020 Jul 27;11(1):3747. doi: 10.1038/s41467-020-17537-2.

    • Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
    • Grzymski JJ, Elhanan G, Morales Rosado JA, Smith E, Schlauch KA, Read R, Rowan C, Slotnick N, Dabe S, Metcalf WJ, Lipp B, Reed H, Sharma L, Levin E, Kao J, Rashkin M, Bowes J, Dunaway K, Slonim A, Washington N, Ferber M, Bolze A, Lu JT.
    • Nat Med. 2020 Jul 27. doi: 10.1038/s41591-020-0982-5. Epub ahead of print.

    • FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
    • Guo E, Ishii Y, Mueller J, Srivatsan A, Gahman T, Putnam CD, Wang JYJ, Kolodner RD.
    • Proc Natl Acad Sci U S A. 2020 Jul 27:202009237. doi: 10.1073/pnas.2009237117. Epub ahead of print.

    • Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    • Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, Lee KH, Kim S, Im SA.
    • Sci Rep. 2020 Jul 27;10(1):12506. doi: 10.1038/s41598-020-68176-y.

    • The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
    • Zhao Y, Zhang LX, Jiang T, Long J, Ma ZY, Lu AP, Cheng Y, Cao DS.
    • Eur J Med Chem. 2020 Jul 15;203:112570. doi: 10.1016/j.ejmech.2020.112570. Epub ahead of print.
    • Review

    • Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.
    • Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, Zhao M, Yang Q, Wang Y, Yang X.
    • Front Oncol. 2020 Jul 3;10:954. doi: 10.3389/fonc.2020.00954.

    • LitAlert ~~ GeneLit.com

    • Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    • Zhang J, Yao L, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Jul 28. doi: 10.1002/ijc.33234. Epub ahead of print.

    • Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
    • Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I.
    • Ann Surg Oncol. 2020 Jul 27. doi: 10.1245/s10434-020-08889-6. Epub ahead of print.

    • Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
    • Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, Chatterjee-Paer S, Carlson AD, Holcomb KM.
    • J Gen Intern Med. 2020 Jul 27. doi: 10.1007/s11606-020-06064-x. Epub ahead of print.